https://www.selleckchem.com/pr....oducts/CP-690550.htm
09 [1.20-3.63]; P = 0.009) and cardiovascular events (HR 2.73 [1.16-6.43]; P = 0.021). Metformin showed a protective association against HCC (HR 0.32 [0.11-0.96]; P = 0.043), which was confirmed after adjustment for propensity score (P = 0.038). Diabetes diagnosis further refined HCC prediction in patients with compensated advanced chronic liver disease at high baseline risk (P = 0.024). Conclusion Metabolic comorbidities were associated with advanced liver fibrosis at baseline, whereas statins were protective. In patients with advanc
إعجاب
علق
شارك
